Prostate Cancer
Conditions
Brief summary
To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.
Interventions
DEVICEmyocardial PET imaging
using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
51 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Either clinically localized prostate cancer or biochemically-recurrent prostate cancer patients who are planned for at least 6 months ADT with a GnRH agonist and curative-intent radiation therapy per their oncologic providers. * Over 50 years of age. Calculated 10-year Framingham General Cardiovascular Risk Score of ≥10% at the time of planned initiation of ADT. * Patients must be able to read and understand English. * Participants must sign the informed consent form.
Exclusion criteria
* Prior treatment with GnRH agonist therapy. * History of active asthma or other reactive airway disease. * Ischemic cardiac event (myocardial infarction, unstable angina) within the preceding 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of subjects who successfully complete Rb-82 myocardial PET Imaging assessments | 12-18 months |
Countries
United States
Outcome results
None listed